Spots Global Cancer Trial Database for Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
Official Title: A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Study ID: NCT01104675
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
University of Colorado Cancer Center, Aurora, Colorado, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Dana Farber/Partners Cancer Care, Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Princess Margaret Hospital, Toronto, Ontario, Canada
Contact Details
Name: William Gannon, MD, MBA
Affiliation: CASI Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
